GlassScriptPhysician profile
Julia Regalado
NPI 1437886488
$931.23
in general payments reported to CMS, 2019-2025
24 companies · $931 in 2025
The $931 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.23 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.00 | 2025 | |
| Janssen Biotech, INC. | $64.95 | 2025 | Carvykti, Rybrevant, Tecvayli |
| Merck Sharp & Dohme LLC | $64.87 | 2025 | Keytruda, Welireg |
| Syndax Pharmaceuticals, INC. | $57.49 | 2025 | Revuforj |
| Servier Pharmaceuticals LLC | $53.41 | 2025 | |
| Daiichi Sankyo INC. | $45.31 | 2025 | Datroway |
| Blueprint Medicines Corporation | $44.54 | 2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $39.51 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $36.46 | 2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $34.86 | 2025 | Fruzaqla |
| Lilly USA, LLC | $32.68 | 2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $32.06 | 2025 | Imfinzi |
| Pharmaessentia USA Corporation | $31.62 | 2025 | Besremi |
| Eisai INC. | $30.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.82 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $30.77 | 2025 | |
| Taiho Oncology, INC. | $30.51 | 2025 | |
| Karyopharm Therapeutics INC. | $27.95 | 2025 | Xpovio |
| Genmab U.S., INC. | $27.10 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $26.45 | 2025 | Zejula, Jemperli |
| Incyte Corporation | $25.69 | 2025 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $24.68 | 2025 | |
| Kyowa Kirin, INC. | $22.94 | 2025 | |
| Secura Bio, INC. | $16.69 | 2025 | Copiktra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Regalado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.